相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
Julio Delgado et al.
ONCOLOGIST (2021)
Acalabrutinib in treatment-naive chronic lymphocytic leukemia
John C. Byrd et al.
BLOOD (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman et al.
LEUKEMIA (2021)
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
Hussein A. Abbas et al.
FRONTIERS IN ONCOLOGY (2021)
Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves
Neda Alrawashdh et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Acalabrutinib ± obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naive chronic lymphocytic leukemia: Elevate-TN four-year follow up.
Jeff Porter Sharman et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia
Candida Vitale et al.
CANCERS (2021)
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Francesca Romana Mauro et al.
CANCERS (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
CANCER DISCOVERY (2020)
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
Clare Sun et al.
BLOOD (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase II study demonstrating durable remissions and long-term tolerability.
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Paolo Ghia et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors
Christopher Pleyer et al.
LEUKEMIA & LYMPHOMA (2020)
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis
Zhixin Sheng et al.
LEUKEMIA & LYMPHOMA (2020)
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia
Stefania Fiorcari et al.
FRONTIERS IN IMMUNOLOGY (2020)
Managing toxicities of Bruton tyrosine kinase inhibitors
Andrew Lipsky et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2020)
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
Valentina Griggio et al.
FRONTIERS IN IMMUNOLOGY (2020)
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
Jennifer Series et al.
HAEMATOLOGICA (2019)
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis
Daniel Caldeira et al.
PLOS ONE (2019)
Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees
Krish Patel et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Hypertension and incident cardiovascular events following ibrutinib initiation
Tyler Dickerson et al.
BLOOD (2019)
Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia
Jan A. Burger et al.
BLOOD (2019)
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Carol Moreno et al.
LANCET ONCOLOGY (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
V. K. Patel et al.
LEUKEMIA (2018)
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids et al.
CLINICAL CANCER RESEARCH (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
Physical Activity Guidelines for Americans From the US Department of Health and Human Services Cardiovascular Benefits and Recommendations
Katrina L. Piercy et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Invasive Fungal Infections in Patients with Chronic Lymphoproliferative Disorders in the Era of Target Drugs
Davide Facchinelli et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2018)
Ibrutinib-Associated Atrial Fibrillation
Sarju Ganatra et al.
JACC-CLINICAL ELECTROPHYSIOLOGY (2018)
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
Allard Kaptein et al.
BLOOD (2018)
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E. M. Herman et al.
CLINICAL CANCER RESEARCH (2017)
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Viralkumar Patel et al.
CLINICAL CANCER RESEARCH (2017)
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
Josee Golay et al.
HAEMATOLOGICA (2017)
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
Josee Golay et al.
HAEMATOLOGICA (2017)
Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib
Alexander P. Bye et al.
BLOOD ADVANCES (2017)
Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL
Paul M. Barr et al.
BLOOD (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia
Inhye E. Ahn et al.
BLOOD (2017)
Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib
Inhye E. Ahn et al.
BLOOD (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia
Stefania Fiorcari et al.
ONCOTARGET (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib
Clare Sun et al.
BLOOD (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages
Mercedes Borge et al.
HAEMATOLOGICA (2015)
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Fabio Da Roit et al.
HAEMATOLOGICA (2015)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity
Holbrook E. Kohrt et al.
BLOOD (2014)
Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B-cell receptor signaling as a driver of lymphoma development and evolution
Carsten U. Niemann et al.
SEMINARS IN CANCER BIOLOGY (2013)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Reduced Phosphoinositide 3-Kinase (p110α) Activation Increases the Susceptibility to Atrial Fibrillation
Lynette Pretorius et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Signaling network of the Btk family kinases
Y Qiu et al.
ONCOGENE (2000)
分享论文
